Publications by authors named "K Lueckerath"
Article Synopsis
- Lu-PSMA therapy is a promising treatment for advanced prostate cancer but has a 30% non-responder rate, leading to investigation of combining it with PD-L1 inhibition to enhance effectiveness.
- A study conducted from March 2018 to December 2021 analyzed 168 patients, focusing on the immune-related signatures in a subset with RNA analysis, revealing that PD-L1 did not significantly impact overall survival (OS), whereas PD-L2 was positively associated with longer OS and better PSA response.
- The findings suggest that a higher PD-L2 signature may improve outcomes with Lu-PSMA therapy, indicating the need for further research into its potential benefits alongside immunotherapy approaches.
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising option for metastatic castration-resistant prostate cancer. Clinical experience using Lu or Ac has demonstrated encouraging treatment responses; however, responses are not durable. Dual-isotope combinations, or "tandem" approaches, may improve tolerability while retaining a high tumor dose.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied two types of scans (F-FDG PET/CT and Ga-FAPI PET/CT) to check how well they find cancer in lymph nodes.
- They found that the Ga-FAPI scan was better at identifying actual cancer in the lymph nodes compared to the F-FDG scan.
- This means that using Ga-FAPI PET/CT could help doctors stage cancer more accurately in patients.
Management of cholangiocarcinoma is among other factors critically determined by accurate staging. Here, we aimed to assess the accuracy of PET/CT with the novel cancer fibroblast-directed Ga-fibroblast activation protein (FAP) inhibitor (FAPI)-46 tracer for cholangiocarcinoma staging and management guidance. Patients with cholangiocarcinoma from a prospective observational trial were analyzed.
View Article and Find Full Text PDFWe present an overview of our prospective fibroblast-activation protein inhibitor (FAPI) registry study across a 3-y period, with head-to-head comparison of tumor uptake in Ga-FAPI and F-FDG PET, as well as FAP immunohistochemistry. This is an interim analysis of the ongoing Ga-FAPI PET prospective observational trial at our department. Patients who underwent clinical imaging with Ga-FAPI PET between October 2018 and October 2021 were included.
View Article and Find Full Text PDF